Sildenafil - Pfizer

Drug Profile

Sildenafil - Pfizer

Alternative Names: Revatio; Revatio IV; Sildenafil citrate; UK 92480; Viagra

Latest Information Update: 25 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; University of Calgary
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heart failure; Pulmonary arterial hypertension; Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Heart failure; Pulmonary hypertension
  • No development reported Female infertility; Raynaud's disease
  • Discontinued Angina pectoris; Cardiovascular disorders; Eye-Disorders; Female sexual dysfunction; Meniere's disease

Most Recent Events

  • 12 Mar 2018 Pfizer completes a phase III trial for Pulmonary arterial hypertension (In infants, In children, In adolescents) in Japan (PO) (NCT01642407)
  • 12 Mar 2018 Phase-III clinical trials in Heart failure (Prevention) in Canada (PO) (NCT03356353)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Female-infertility in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top